Huadong Medicine's (SHE:000963) unit, Zhejiang Daer Biotechnology, received approval from China's National Medical Products Administration for the clinical trial of DR30206, according to a Shenzhen bourse filing over the weekend.
The Chinese drugmaker's shares rose 1% during Monday's afternoon trade.
The drug is developed as a treatment for patients with locally advanced or unresectable Stage III non-small cell lung cancer.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments